Compare YUM & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YUM | EW |
|---|---|---|
| Founded | 1997 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.7B | 49.5B |
| IPO Year | 1997 | 1999 |
| Metric | YUM | EW |
|---|---|---|
| Price | $150.26 | $85.04 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 21 |
| Target Price | ★ $168.87 | $96.37 |
| AVG Volume (30 Days) | 1.6M | ★ 4.5M |
| Earning Date | 04-29-2026 | 04-23-2026 |
| Dividend Yield | ★ 1.88% | N/A |
| EPS Growth | ★ 6.32 | N/A |
| EPS | ★ 1.55 | 0.66 |
| Revenue | ★ $8,214,000,000.00 | $6,067,600,000.00 |
| Revenue This Year | $12.11 | $13.39 |
| Revenue Next Year | $5.84 | $9.81 |
| P/E Ratio | ★ $95.48 | $132.61 |
| Revenue Growth | 8.81 | ★ 11.55 |
| 52 Week Low | $137.33 | $72.30 |
| 52 Week High | $169.39 | $89.14 |
| Indicator | YUM | EW |
|---|---|---|
| Relative Strength Index (RSI) | 45.80 | 52.83 |
| Support Level | $148.48 | $81.39 |
| Resistance Level | $155.61 | $87.22 |
| Average True Range (ATR) | 2.93 | 2.41 |
| MACD | -0.08 | 0.14 |
| Stochastic Oscillator | 48.93 | 51.68 |
As of the end of 2025, Yum Brands generated over $68 billion in systemwide sales from more than 63,000 restaurants across 155 markets, making it the world's second-largest restaurant firm by dollar sales. Its portfolio includes KFC (33,897 stores), Pizza Hut (19,974), Taco Bell (9,030), and Habit Burger (384), with 72% of locations in international markets. As 97% of its portfolio is franchised, Yum's business model is tilted toward recurring franchise royalties and marketing contributions (64% of revenue), with the balance derived from sales at company-owned locations. The company traces its roots to a 1997 spinoff of PepsiCo's restaurant assets.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.